| 1 |
NCT02880462 |
Not yet recruiting |
A 6-month Study to Evaluate Sulforaphane add-on Effects in Treatment of Schizophrenia |
|
- Dietary Supplement: sulforaphane
- Other: placebo
|
Interventional
|
Phase 2
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Cognitive improvement assessed using the MATRICS Consensus Cognitive Battery (MCCB) composite score
- side effects by SAFTEE
- side effects by AIMS
- (and 4 more...)
|
180 |
All |
18 Years to 50 Years (Adult) |
NCT02880462 |
Stanley-Sulforaphane |
|
September 2016 |
December 2019 |
December 2019 |
August 26, 2016 |
August 26, 2016 |
|
|
|
| 2 |
NCT03730649 |
Not yet recruiting |
Effect of Topical Sulforaphane on Skin Aging and With Ultraviolet and Visible Light Exposure |
|
- Drug: Sulforaphane (broccoli sprout extract)
- Radiation: UV or visible light
|
Interventional
|
Early Phase 1 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- keratin 16 presence as determined by immunofluorescence assay
- keratin 17 presence as determined by immunofluorescence assay
- keratin 16 fold change as determined by Reverse Transcription Polymerase Chain Reaction (RT-PCR)
- (and 2 more...)
|
120 |
All |
18 Years and older (Adult, Older Adult) |
NCT03730649 |
IRB00184806 |
|
April 2019 |
September 2024 |
September 2024 |
November 5, 2018 |
March 15, 2019 |
|
- Cutaneous Translational Research Program, Department of Dermatology, Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
|
|
| 3 |
NCT02909959 |
Recruiting |
Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder |
- Autism Spectrum Disorder
- Autistic Disorder
- Neurodevelopmental Disorder
- Childhood Developmental Disorders, Pervasive
|
- Drug: Sulforaphane
- Drug: Placebo
|
Interventional
|
Phase 2 |
- University of North Carolina, Chapel Hill
- North Carolina Translational and Clinical Sciences Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Social Responsiveness Scale-2 (SRS-2) total scores from baseline to weeks 4, 8, 12 and 16.
- Change in SRS-2 subscale scores (Social Awareness, Social Cognition, Social Communication, Social Motivation, and Restricted Interests/ Repetitive Behaviors) from baseline to weeks 4, 8, 12 and 16.
- Change in Aberrant Behavior Checklist (ABC) subscale scores (Social Withdrawal, Hyperactivity, Inappropriate Speech, Stereotypy, and Irritability) from baseline to weeks 4, 8, 12, and 16.
- (and 9 more...)
|
54 |
Male |
13 Years to 30 Years (Child, Adult) |
NCT02909959 |
16-2059
5KL2TR001109-05 |
|
March 1, 2017 |
November 2019 |
November 2019 |
September 21, 2016 |
May 17, 2018 |
|
- Carolina Institute for Developmental Disabilities, University of North Carolina School of Medicine
Carrboro, North Carolina, United States
|
|
| 4 |
NCT03232138 |
Recruiting |
Clinical Trial of Lung Cancer Chemoprevention With Sulforaphane in Former Smokers |
|
- Drug: Sulforaphane
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Jian-Min Yuan
- National Cancer Institute (NCI)
- University of Pittsburgh
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Bronchial dysplasia index
- Cell proliferation marker Ki-67
- Apoptosis markers including caspase-3 and TUNEL
- (and 4 more...)
|
72 |
All |
55 Years to 75 Years (Adult, Older Adult) |
NCT03232138 |
16-135
R01CA213123 |
|
January 25, 2018 |
September 30, 2021 |
September 30, 2022 |
July 27, 2017 |
October 9, 2018 |
|
- UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
|
|
| 5 |
NCT02677051 |
Recruiting |
Sulforaphane in a New Jersey (NJ) Population of Individuals With Autism |
- Autism
- Autistic Disorder
- Autism Spectrum Disorder
- Autistic Behavior
|
- Drug: Sulforaphane
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Rutgers, The State University of New Jersey
- Rowan University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Aberrant Behavior Checklist (ABC) scores.
- Change in Social Responsiveness Scale (SRS) scores.
- Clinical Global Impression Severity Scale (CGI-S).
- (and 4 more...)
|
40 |
Male |
13 Years to 30 Years (Child, Adult) |
NCT02677051 |
Pro20120001884
CAUT15APL013 |
|
February 2016 |
December 2018 |
January 2022 |
February 9, 2016 |
December 13, 2018 |
|
- Rutgers University - Staged Research Building
Piscataway, New Jersey, United States
|
|
| 6 |
NCT02879110 |
Recruiting |
A 12-weeks Study to Evaluate Sulforaphane in Treatment of Autism Spectrum Disorder |
|
- Dietary Supplement: Sulforaphane
- Other: Placebo
|
Interventional
|
Not Applicable |
- Central South University
- Davis family funding
- University of California
- University of Illinois at Chicago
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The change of social impairments of children with autism spectrum disorder
- The change of rigid interests and behaviors of children with autism spectrum disorder
- The change of clinical symptoms of children with autism spectrum
- (and 16 more...)
|
120 |
All |
3 Years to 15 Years (Child) |
NCT02879110 |
ASD201512 |
|
August 2016 |
August 2019 |
August 2019 |
August 25, 2016 |
November 27, 2018 |
|
- Guangzhou Huiai Hospital
Guangzhou, Guangdong, China - The second Xiangya hospital of central south university
Changsha, Hunan, China
|
|
| 7 |
NCT03517995 |
Not yet recruiting |
Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention |
- Bladder Cancer
- Bladder Tumor
- Urothelial Carcinoma
|
- Drug: Sulforaphane Administration
- Other: Placebo Administration
- Procedure: Standard of Care Surgery
|
Interventional
|
Phase 2 |
- H. Lee Moffitt Cancer Center and Research Institute
- National Institutes of Health (NIH)
- Johns Hopkins University
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Magnitude of Change
- Effectiveness of Sulforaphane vs. Placebo
- Occurrence of Adverse Events per Study Arm
- (and 4 more...)
|
135 |
All |
18 Years and older (Adult, Older Adult) |
NCT03517995 |
MCC-19574 |
|
September 2019 |
December 2021 |
December 2022 |
May 8, 2018 |
April 3, 2019 |
|
- H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States - James A. Haley Veteran's Administration Hospital
Tampa, Florida, United States
|
|
| 8 |
NCT03878368 |
Not yet recruiting |
Broccoli In Osteoarthritis |
|
- Dietary Supplement: Sulforaphane
- Dietary Supplement: Placebo
|
Interventional
|
Not Applicable |
- University of East Anglia
- University of Leeds
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- WOMAC (Western Ontario and McMaster Universities Arthritis Index)
- WOMAC (Western Ontario and McMaster Universities Arthritis Index): Pain
- WOMAC (Western Ontario and McMaster Universities Arthritis Index): Physical Function
- (and 9 more...)
|
64 |
All |
50 Years and older (Adult, Older Adult) |
NCT03878368 |
BRIO Protocol V1.0 (22 |
BRIO |
May 1, 2019 |
April 30, 2020 |
June 1, 2020 |
March 18, 2019 |
March 20, 2019 |
|
|
|
| 9 |
NCT03665922 |
Not yet recruiting |
Biomarkers of Sulforaphane/Broccoli Sprout Extract in Prostate Cancer |
|
- Dietary Supplement: BroccoMax®
- Other: Placebo
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Palmitic Acid Reduction
- Evaluation of safety of BroccoMax® (side effects or adverse events)
- Serum SFN levels
- (and 6 more...)
|
40 |
Male |
18 Years to 90 Years (Adult, Older Adult) |
NCT03665922 |
PRO18040423 |
|
May 1, 2019 |
June 15, 2023 |
January 15, 2024 |
September 11, 2018 |
March 25, 2019 |
|
- Shadyside Urology
Pittsburgh, Pennsylvania, United States
|
|
| 10 |
NCT03220542 |
Recruiting |
The Effect of Broccoli Sprout Extract and Probiotics for Eradication of Helicobacter Pylori |
- Helicobacter Pylori Infection
|
- Drug: Probiotics
- Dietary Supplement: Broccoli
- Drug: Esomeprazole
- (and 2 more...)
|
Interventional
|
Phase 4 |
- Kyunghee University Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Helicobacter pylori eradication
|
360 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03220542 |
Broccoli2014 |
|
January 2016 |
October 2017 |
December 2017 |
July 18, 2017 |
July 18, 2017 |
|
- Kyung Hee University Hospital
Seoul, Korea, Republic of
|
|
| 11 |
NCT03289832 |
Recruiting |
Effect of Orally Delivered Phytochemicals on Aging and Inflammation in the Skin |
|
- Dietary Supplement: Crucera-SGS
- Dietary Supplement: Meriva 500-SF
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change in Erythema 1 Day After UV Exposure
- Change in Erythema 2 Days After UV Exposure
- Change in Erythema 3 Days After UV Exposure
- (and 8 more...)
|
18 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03289832 |
IRB00117754 |
|
September 25, 2017 |
September 22, 2019 |
December 1, 2019 |
September 21, 2017 |
December 20, 2018 |
|
- Johns Hopkins
Baltimore, Maryland, United States
|
|
| 12 |
NCT03763240 |
Recruiting |
BSE on Blood Glucose |
|
- Dietary Supplement: BSE
- Dietary Supplement: Placebo
|
Interventional
|
Not Applicable |
- Region Skane
- Göteborg University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The primary effect variable is venous fasting blood glucose.
|
100 |
All |
35 Years to 75 Years (Adult, Older Adult) |
NCT03763240 |
BSE |
|
September 1, 2018 |
December 1, 2020 |
December 1, 2020 |
December 4, 2018 |
December 4, 2018 |
|
- Gothia Forum
Gothenburg, Sweden
|
|
| 13 |
NCT03649802 |
Not yet recruiting |
Vitamin D and Arterial Stiffness in Elderly |
- Vitamin D Deficiency
- Arterial Stiffness
|
- Dietary Supplement: Low dose vitamin D3
- Dietary Supplement: High dose vitamin D3
|
Interventional
|
Phase 2 |
- Texas Tech University Health Sciences Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Carotid-femoral pulse wave velocity measured by equipment provided by Complior pulse wave analysis
- 24 hour BP ambulatory monitoring
- Heart rate variability
- Plasma sulphoraphane and F2-isoprostanes. Isoprostanes will be measured by gas chromatography mass spectrometry and sulphoraphane will be measured using LC-MS/MS techniques
|
52 |
All |
65 Years to 89 Years (Older Adult) |
NCT03649802 |
L18-174 |
|
June 1, 2019 |
December 31, 2021 |
December 31, 2021 |
August 28, 2018 |
January 29, 2019 |
|
- Texas Tech University Health Sciences Center
Lubbock, Texas, United States
|
|
| 14 |
NCT02614742 |
Recruiting |
SFX01 After Subarachnoid Haemorrhage |
- Subarachnoid Hemorrhage, Spontaneous
|
- Drug: SFX-01
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of participants with treatment-related adverse events as assessed by Common Toxicity Criteria
- Maximum CSF Concentration [Cmax],
- Number of participants with treatment related reduction in middle cerebral artery (MCA) peak flow velocity following Subarachnoid Haemorrhage (SAH) measured by trans cranial doppler ultrasound
- (and 5 more...)
|
90 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02614742 |
EVG001SAH
2014-003284-38 |
SAS |
April 2016 |
March 2019 |
April 2019 |
November 25, 2015 |
August 2, 2018 |
|
- Southampton General Hospital
Southampton, Hampshire, United Kingdom - Queen Elizabeth Hospital
Birmingham, United Kingdom - Western General Hospital
Edinburgh, United Kingdom - The Royal London Hospital
London, United Kingdom
|
|
| 15 |
NCT03182959 |
Recruiting |
Broccoli Sprout Extract in Preventing Recurrence in Patients With Tobacco-Related Head and Neck Squamous Cell Cancer |
- HNSCC
- Head and Neck Cancer
- Head and Neck Squamous Cell Carcinoma
- (and 5 more...)
|
|
Interventional
|
Early Phase 1 |
- University of Arizona
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Determine whether Avmacol® results in acute and/or sustained induction of NRF2 target gene transcripts in the oral mucosa of patients who have been curatively treated for a tobacco-related HNSCC.
- Determine whether NRF2 target protein expression is upregulated by Avmacol® in the oral mucosa.
- Evaluate for a dose-response relationship between Avmacol® dose and quantitative change in candidate NRF2 pathway biomarkers in oral mucosa.
- (and 10 more...)
|
36 |
All |
18 Years and older (Adult, Older Adult) |
NCT03182959 |
1612032762
5P50CA097190 |
|
April 24, 2017 |
December 31, 2019 |
December 31, 2019 |
June 9, 2017 |
November 22, 2018 |
|
- The University of Arizona Cancer Center
Tucson, Arizona, United States
|
|
| 16 |
NCT03402230 |
Recruiting |
Broccoli Sprout/Broccoli Seed Extract Supplement in Decreasing Toxicity in Heavy Smokers |
- Current Every Day Smoker
- Tobacco Smoking
|
- Drug: Broccoli Sprout/Broccoli Seed Extract Supplement
- Other: Laboratory Biomarker Analysis
- Other: Questionnaire Administration
|
Interventional
|
Early Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Change in urinary excretion of the mercapturic acid of benzene
- Changes in the urinary excretion of the mercapturic acids of acrolein and crotonaldehyde
- Urinary excretion of the mercapturic acids of tobacco carcinogens
- (and 3 more...)
|
61 |
All |
18 Years and older (Adult, Older Adult) |
NCT03402230 |
NCI-2017-02406
N01-CN-2012-00031
1711022046
UAZ2017-09-02
N01CN00031
P30CA023074 |
|
February 20, 2018 |
November 30, 2020 |
November 30, 2020 |
January 18, 2018 |
February 6, 2019 |
|
- The University of Arizona Medical Center-University Campus
Tucson, Arizona, United States
|
|
Create an RSS feed from your search for:
Download the search results for: